Navidea's Macrophage heralds preclinical drug conjugate for Kaposi's sarcoma; Biogen links up with AGTC on blindness gene therapy;

> Macrophage Therapeutics, part of Navidea ($NAVB), announced preclinical results from its study of doxorubicin linked to its drug conjugate Manocept as a treatment for Kaposi's sarcoma. Release

> Biogen ($BIIB) and AGTC have joined forces to develop gene therapies for ophthalmologic use. AGTC's main foci are diseases of the retina that can lead to blindness. Release